Company Overview of Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. The company operates primarily in Israel. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and i...
Hi-Tech Park 2/4
PO Box 39098
Founded in 2002
Key Executives for Oramed Pharmaceuticals Inc.
Chief Executive Officer, President and Executive Director
Total Annual Compensation: $468.8K
Chief Financial Officer, Treasurer and Secretary
Total Annual Compensation: $140.9K
Chief Operating Officer and Vice President of Business Development
Total Annual Compensation: $219.3K
Chief Medical & Technology Officer, Chief Scientific Officer and Director
Total Annual Compensation: $340.0K
Compensation as of Fiscal Year 2016.
Oramed Pharmaceuticals Inc. Key Developments
Oramed Pharmaceuticals Inc. Presents at Oppenheimer 17th Annual Israel Conference, May-21-2017 12:00 PM
May 18 17
Oramed Pharmaceuticals Inc. Presents at Oppenheimer 17th Annual Israel Conference, May-21-2017 12:00 PM. Venue: David Intercontinental Tel-Aviv Hotel, Tel Aviv, Israel. Speakers: Nadav Kidron, Chief Executive Officer, President and Executive Director.
Canadian Intellectual Property Office Grants Patent for Oral Glucagon-Like Peptide-1 Analog of Oramed Pharmaceuticals Inc
May 9 17
Oramed Pharmaceuticals Inc. announced that the Canadian Intellectual Property Office has granted Oramed a patent titled, 'Methods and Compositions for Oral Administration of Exenatide'. The patent covers Oramed's invention of an oral glucagon-like peptide-1 (GLP-1) analog. GLP-1 is an incretin hormone that stimulates the secretion of insulin from the pancreas. Exenatide, a GLP-1 analog, is currently marketed in injectable form only, and is indicated for treatment of type 2 diabetes. Exenatide induces insulin release at increased glucose levels and causes a feeling of satiety, which results in reduced food intake and weight loss. Oramed's oral GLP-1 capsule based on the Company's Protein Oral Delivery (PODTM) technology could significantly increase compliance and become a valuable tool in the treatment of diabetes.
Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule
May 2 17
Oramed Pharmaceuticals Inc. announced that based on positive preclinical data, the company is developing a new drug candidate, a weight loss treatment in the form of an oral leptin capsule. Leptin, also known as the "obesity hormone" is a protein that regulates hunger. Israel's Ministry of Health has approved Oramed's commencement of a proof of concept single dose study for its oral leptin drug candidate to evaluate its pharmacokinetic and pharmacodynamics (glucagon reduction) in ten type 1 diabetic patients.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries